CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Summit Therapeutics reports Q3 loss on higher R&D spending

By Reuters News


Overview

  • US oncology drugmaker posted Q3 net loss as R&D expenses rose on expanded clinical trials

  • Company received $2 bln equity investment from AstraZeneca after quarter-end to fund ivonescimab development

  • Company ended Q3 with $629.8 mln in cash and investments


Outlook

  • FDA decision on ivonescimab BLA expected by Nov 14, 2026

  • Company expects primary analysis for HARMONi-3 squamous NSCLC cohort in Q4 2026

  • Company expects PFS analysis for HARMONi-3 non-squamous NSCLC cohort in H1 2027


Result Drivers

  • CLINICAL TRIAL EXPANSION - Co said higher R&D expenses were mainly due to expanded clinical studies and development costs for ivonescimab

  • INFRASTRUCTURE AND HEADCOUNT - Co said G&A expense increase was driven by expanded infrastructure and headcount to support ivonescimab development


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.26

Q3 Net Loss

$208.40 mln

Q3 Operating Expenses

$214.60 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Summit Therapeutics Inc. is $32.00, about 102.5% above its November 3 closing price of $15.80


Reuters Recommended Reads

  • Nov 4 - Aprea Therapeutics Q3 net loss widens on higher R&D spending

  • Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

  • Nov 4 - Cytokinetics Q3 net loss narrows as net product revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.